Yes so true. Targeting one or even several cancer antigens is never going to cut it. We have seen other treatments that do this, not with a toxic payload, but just by activating our immune system to target these select antigens. What typically happens is there will be some initial improvement but then the cancer returns with vengeance as it mutates into a form without those select antigens. Now if they had some type of process like DCVAX that targets the full spectrum of cancer antigens that they could tune for each patient then they might have something . . . but not seeing how they could do that. GOOD LUCK & Merry Christmas Flip!!! Hopefully we will be getting new on approval soon soon.
I agree flipper44, I also believe that ADCs are a new way for big pharma to continue to poison cancer patients, and profit off of toxic treatments, while harming patients’ immune system and its ability to fight cancer.
Just because a monster (chemo) is outfitted in a pretty dress, with a wig and has lipstick on (ADCs), does not mean it is not still a monster.
If I was a solid tumor cancer patient, my first preference would be maximal safe tumor resection, then to be treated with true immunotherapy like DCVax-L and/or DCVax-Direct, a TME pre-conditioning regimen along with immune-boosting agents.
Market Data 
Markets 
AI
